Compare Gilead Sciences, Inc. (GILD) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ross Stores, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while Ross Stores, Inc. trades at $233.22 (market cap $72.47B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× Ross Stores, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | ROST | |
|---|---|---|
Market Cap | $163.51B | $72.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $240.13 |
52-Week Low | $108.22 | $129.10 |
Enterprise Value | $178.05B | $73.07B |
Dividend Yield | 2.49% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Ross Stores (ROST) trades at $232.89, up 5.43% today, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows bullish technical signals with support at $223 and resistance at $233. Fundamentally, ROST demonstrates robust profitability with a 38.98% ROE and 9.74% net margin, supported by revenue growth to $21.13B in 2025. Recent news highlights include a Zacks Strong Buy upgrade on June 15, 2026, and inclusion in high-ROE stock lists amid market volatility.
The outlook for ROST remains positive with a consensus price target of $259, suggesting 11% upside. Key opportunities include sustained earnings growth and expanding store footprint, while risks involve consumer spending sensitivity and competitive pressures. Institutional sentiment is bullish with 64% buy ratings, though elevated P/E of 31.55 warrants valuation monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
